FOLD Amicus Therapeutics, Inc.

+0  (3%)
Previous Close 7.02
Open 7.01
Price To book 2.78
Market Cap 1.42B
Shares 194,824,000
Volume 2,561,981
Short Ratio 12.94
Av. Daily Volume 3,424,550

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
Migalastat HCl monotherapy (012)
Fabry Disease
"Phase 3 top-line data due mid 2017.
Epidermolysis Bullosa (EB)
Phase 1/2 additional data released February 15, 2017. Further data due 2Q and 3Q 2017.
Pompe Disease

Latest News

  1. Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics
  2. Are These 2 Biotechs Diamonds in the Rough?
  3. Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy
  4. AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Harry Boxer’s six biotechnology stocks to watch
  7. Four biotech stocks surging on optimism about drug trials, product launches
  8. Biotechs Breaking Out On Drug Development News
  9. Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA
  10. Dow Soars Above 21,000 for the First Time in History: Today's Reports on Clean Energy Fuels and Amicus Therapeutics
  11. Amicus Therapeutics to Present at Upcoming Investor Conferences
  12. Edited Transcript of FOLD earnings conference call or presentation 1-Mar-17 1:30pm GMT
  13. Amicus Therapeutics CEO: Trump constructive for our indus...
  14. Why Amicus Therapeutics, Inc. Jumped Higher Today
  15. 4 Biopharma Stocks Moving the Market on Wednesday
  16. AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  17. Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
  18. Q4 2016 Amicus Therapeutics Inc Earnings Release - Before Market Open
  19. Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates
  20. Amicus Therapeutics Launches Galafold in UK